SCHEMBL2201674

SCHEMBL2201674

Cc1c(C(=O)N2CCN(CCCO)CC2)nn(C)c1-c1ccccc1-c1cc2ccccc2o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 4/20 0.40
DRD2 P14416 3/20 0.40
HRH4 Q9H3N8 1/20 0.40
ALDH1A1 P00352 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 3/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
MKNK1 Q9BUB5 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201258 0.95 ALDH1A1 (0.42) DRD3DRD2HRH4ALDH1A1SMN1; SMN2
SCHEMBL2200712 0.91 GRIN2B (0.44) DRD3DRD2HRH4ALDH1A1SMN1; SMN2
SCHEMBL2202074 0.89 ALDH1A1 (0.47) DRD3DRD2HRH4ALDH1A1SMN1; SMN2
SCHEMBL2201671 0.88 DRD3 (0.39) DRD3DRD2HRH4ALDH1A1SMN1; SMN2
SCHEMBL2201254 0.82 ALDH1A1 (0.41) DRD3DRD2HRH4ALDH1A1SMN1; SMN2
SCHEMBL2200710 0.80 GRIN2B (0.43) DRD3DRD2HRH4ALDH1A1SMN1; SMN2
SCHEMBL2197343 0.79 EIF4E (0.51) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL2199010 0.79 KDM4E (0.45) ALDH1A1SMN1; SMN2KDM4ETSHRMEN1
SCHEMBL3689666 0.78 POLR1A (0.41) ALDH1A1SMN1; SMN2TSHRHPGDMAPT
SCHEMBL2202072 0.77 DRD2 (0.46) DRD3DRD2HRH4ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 DRD3 751/4885DRD2 1088/4885HRH4 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.